Premium
Quinacrine does not prolong survival in a murine Creutzfeldt‐Jakob disease model
Author(s) -
Collins Steven J.,
Lewis Victoria,
Brazier Marcus,
Hill Andrew F.,
Fletcher Ashley,
Masters Colin L.
Publication year - 2002
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.10336
Subject(s) - bovine spongiform encephalopathy , transmissible spongiform encephalopathy , virology , disease , in vivo , encephalopathy , creutzfeldt jakob syndrome , biology , medicine , prion protein , pathology , scrapie , genetics
Paramount among issues relating to the transmissible spongiform encephalopathies (also known as prion diseases) is the absence of any effective therapy. This need has been heightened by the substantial European and emerging global problem of bovine spongiform encephalopathy and consequent variant Creutzfeldt‐Jakob disease. Stimulated by the recent reports of a potent antiprion effect in cell culture–based clearance assays, we studied the utility of quinacrine in a well‐characterized in vivo model of mouse‐adapted transmissible spongiform encephalopathy. Our results failed to show any evidence that quinacrine is effective when using the simple but objective measure of survival prolongation.